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a b s t r a c t
Data from genetically modiﬁed mice suggest that benzodiazepine (BDZ)-site agonists with improved
selectivity for a2-subtype GABAA receptors (a2GABAAR) are potentially useful for the treatment of
neuropathic pain. Subtype-selective compounds available for preclinical tests in rodents support this
concept but have not been approved for human use, hindering proof-of-concept studies in patients. We
recently proposed that N-desmethyl clobazam (NDMC), the main metabolite of the licensed BDZ clo-
bazam (CBZ), is responsible for most of the antihyperalgesia observed in mice after CBZ administration.
In order to assess a potentially favorable pharmacological proﬁle of NDMC, we analyzed differences in
the GABAAR subtype speciﬁcity of CBZ, NDMC and diazepam (DZP) in recombinant receptors. DZP and
CBZ potentiated sedating a1GABAARs and antihyperalgesic a2GABAARs with similar efﬁcacies, whereas
NDMC preferred a2GABAARs over a1GABAARs across a wide concentration range. In vivo, DZP and NDMC
reduced neuropathic pain at doses between 3 and 30 mg/kg. At these doses, DZP had strong locomotor
sedating effects while NDMC caused no or only weak sedation. Sedative effects of NDMC became
apparent when the action of NDMC was restricted to a1GABAARs. However, when GABAAR point-
mutated mice were studied that allow the analysis of antihyperalgesia and sedation in isolation, we
found that, compared to DZP, NDMC had a signiﬁcantly improved therapeutic window, consistent with
its more favorable a2/a1 in vitro activity ratio. Given that NDMC should share the safety proﬁle of its
parent compound CBZ, it should be well-suited for proof-of-concept studies in human volunteers or
patients.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Chronic pain is a medical condition that is often refractory to
currently available pharmacotherapy. In particular neuropathic
pain is resistant to the majority of conventional analgesics, and
drugs that are effective carry a high rate of side-effects. The iden-
tiﬁcation of novel drug targets based on disease mechanisms and
the development of new analgesic drugs targeting the biological
processes that underlie pain offer the opportunity to improve the
current situation.
Many chronic pain states are accompanied by diminished syn-
aptic inhibition at the spinal cord level (Beyer et al., 1985; Roberts
et al., 1986; Sivilotti and Woolf, 1994; Zeilhofer et al., 2012).
Conversely, pharmacological enhancement of GABAergic inhibition
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in the spinal cord through locally applied DZP reverses pathologi-
cally increased pain sensitivity (hyperalgesia) in rodent models of
chronic inﬂammatory and neuropathic pain (Knabl et al., 2008).
The generation of GABAAR point-mutated (“knock-in”) mice which
carry a histidine to arginine (H/ R) point mutation rendering the
mutated GABAARs insensitive to DZP (and many other BDZ site
agonists) has allowed attributing different in vivo actions of BDZ to
different subtypes GABAARs (M€ohler et al., 2002). Analysis of these
mice in different pain models indicated that antihyperalgesic ac-
tions of BDZ occur mainly through spinal a2GABAARs (Knabl et al.,
2008; Paul et al., 2014). Genetically modiﬁed (triple GABAA receptor
point-mutated) mice, in which only one GABAAR subtype was left
BDZ-sensitive, demonstrated that pronounced antihyperalgesia can
be achieved with systemic DZP administration without signs of
sedation or impaired motor coordination when only a2GABAARs
are targeted (Ralvenius et al., 2015). Conversely, many of the typical
side effects of classical BDZ such as sedation, addiction, and motor
impairment depend on activation of a1GABAARs (Ralvenius et al.,
2015; Rudolph et al., 1999; Tan et al., 2010). The observation that
desired and unwanted effects of classical BDZ site agonists are
mediated by distinct GABAAR subtypes has stimulated the devel-
opment of new compounds with improved subtype selectivity
(Rudolph and Knoﬂach, 2011). Such compounds were also evalu-
ated in different preclinical pain models (Di Lio et al., 2011;
Hofmann et al., 2012; Knabl et al., 2008, 2009; Munro et al.,
2009; Nickolls et al., 2011; Paul et al., 2014; Reichl et al., 2012,
reviewed in Zeilhofer et al., 2012) and provided proof-of-concept
evidence that the results obtained in genetically modiﬁed mice
translate into in vivo antihyperalgesic efﬁcacy of novel BDZ site
agonists with improved subtype selectivity.
However, in the light of recent concerns raised about the pre-
dictive value of animal and, in particular, rodent models in pain
research (Tappe-Theodor and Kuner, 2014), it appears important to
obtain proof-of-concept data on the translatability of these ﬁndings
to humans. Classical BDZ site agonists such as clonazepam and CBZ
exert weak analgesic effects when given at standard therapeutic
doses (Besson et al., 2015; Vuilleumier et al., 2013). Our recent
preclinical study (Ralvenius et al., 2015) that compared anti-
hyperalgesic and sedative effects of DZP in genetically modiﬁed
mice suggests that the doses needed to achieve relevant analgesia
can typically not be achieved in human patients because of dose
limiting sedation. Compounds devoid of a1GABAAR-mediated
sedation should circumvent this problem. However, none of the
currently available compounds with improved a2GABAAR selec-
tivity have so far been approved for use in humans. We therefore
evaluated alternative possibilities for proof-of-concept studies in
humans. In a previous preclinical pharmacokinetic/pharmacody-
namic (PK/PD) study on possible antihyperalgesic effects of CBZ we
found that antihyperalgesic effects correlated better with blood
levels of the main metabolite N-desmethyl clobazam (NDMC) than
with blood levels of the parent compound CBZ (Besson et al., 2013).
In the present study, we have systematically evaluated the subtype
selectivity of NDMC in recombinant GABAARs, its antihyperalgesic
effects in a mouse model of neuropathic pain and its propensity
towards sedation. We found that NDMC has a better a2/a1-GABAAR
selectivity-proﬁle than the parent compound CBZ and better than
the canonical BDZ site agonist DZP. This more favorable in vitro
proﬁle translated to profound antihyperalgesic activity at doses
that caused no or only mild sedation. Because NDMC is a naturally
occurring metabolite of CBZ in humans (Grigoleit et al., 1983) and
has already been given in-ﬁrst-in-man clinical studies targeting
patients with treatment refractory epilepsy (Haigh et al., 1987),
NDMC could constitute a suitable tool compound for proof-of-
concept studies exploring its antihyperalgesic potency in chronic
pain conditions in humans.
2. Materials and methods
2.1. Drugs
DZP and CBZ were obtained from Lipomed AG, Arlesheim,
Switzerland. NDMC was obtained from Imaginechem Co, Ltd,
Hangzhou, China. NDMC was tested for purity, which was 99%.
2.2. Mice
Experiments were performed in two strains of wild-type mice
(C57BL/6J and 129X1/SvJ), and in homozygous triple and quadruple
(H/ R) GABAAR point-mutated mice of the 129X1/SvJ background
(Ralvenius et al., 2015). Triple and quadruple point-mutated mice
were generated by cross-breeding of four strains of single point-
mutated mice described previously (Crestani et al., 2002; L€ow
et al., 2000; Rudolph et al., 1999).
2.3. [3H]ﬂunitrazepam binding to transfected HEK293 cells
HEK293 cells (ATCC) were maintained in DMEM/10% FBS and
plated to a density of 800,000 cells onto 10 cm culture dishes 3 h
before transfection with plasmids containing the rat subunits a1,
b2 and g2 or a2, b3 and g2 (8 mg total DNA/culture dish, ratio
1:1:2) using the PEI transfection method. Forty-eight hours after
transfection, HEK293 cells were harvested in PBS for [3H]ﬂuni-
trazepam binding. HEK 293 cells were homogenized in 20 vol
50 mM Tris pH 7.5, protease inhibitor cocktail (complete Mini,
Roche Applied Science) and centrifuged at 500 g for 10 min at
4 C. To obtain the crude membrane fraction, the supernatants
were centrifuged for 20 min at 100,000 g (4 C). The crude
membranes were washed 4 times in 5 mM Tris-HCl pH 7.4,
10 mM EDTA by resuspension and centrifugation and stored at
80 C until used. Crude membranes were then washed once in
50 mM Tris pH 7.5 (containing protease inhibitor cocktail) and
aliquots (~100 mg protein) were incubated with increasing con-
centrations of DZP, CBZ or NDMC and 1 nM [3H]ﬂunitrazepam
(79.8 Ci/mmol, PerkinElmer) in a total volume of 200 ml for
120 min on ice. Subsequently, the samples were ﬁltered onto
glass ﬁber ﬁlters using a 12-channel semiautomated cell
harvester (Scatron) and washed with ice-cold buffer (50 mM Tris-
HCl pH 7.4). Non-speciﬁc [3H]ﬂunitrazepam binding was deter-
mined using 10 mM ﬂumazenil. The radioactivity retained by the
ﬁlters was determined by liquid scintillation counting using a
Tricarb 2500 liquid scintillation analyzer. Binding data were
analyzed using the GraphPad Prism software (version 5.04,
GraphPad Software, USA).
2.4. Electrophysiology
The effects of DZP, CBZ and NDMC on currents through recom-
binant GABAARs were studied in HEK293 cells transiently trans-
fected with rat GABAAR subunits using lipofectamine LTX 46
(Invitrogen). To ensure expression of the g2 subunit (required for
modulation of GABAAR currents by BDZs) in all recorded cells, we
transfected cells with a plasmid expressing the g2 subunit plus
eGFP from an IRES, and selected only eGFP-positive cells for re-
cordings (see also Ralvenius et al., 2015). The transfection mixture
contained (in mg): 1 ax, 1 by, 3 g2/eGFP. Whole-cell patch-clamp
recordings weremade at room temperature (20e24 C) at a holding
potential of -60 mV 18e36 h after transfection 60. Recording
electrodes were ﬁlled with solution containing (in mM): 120 CsCl,
10 EGTA, 10 HEPES (pH 7.40), 4 MgCl2, 0.5 GTP and 2 ATP. The
external solution contained (in mM): 150 NaCl, 10 KCl, 2.0 CaCl2, 1.0
MgCl2, 10 HEPES (pH 7.40), and 10 glucose. GABAwas applied to the
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recorded cell using a manually controlled pulse (6e10 s) of a low
sub-saturating GABA concentration (EC10). EC10 values of GABA
were 1 mM, 5 mM, 8 mM, and 1 mM for the four GABAAR combinations
(a1b2g2, a2b3g2, a3b3g2 and a5b2g2), respectively. EC50 values
and Hill coefﬁcients (nH) were obtained from ﬁts of normalized
concentration-response curves to the Hill equation IGABA ¼ Imax
[GABA]nH/([GABA]nH þ [EC50]nH). Imax was determined as the
average maximal current elicited by saturating concentration of
GABA (30 mMe3 mM, depending on the subunit composition). DZP,
CBZ and NDMC were dissolved in DMSO (ﬁnal concentra-
tion < 0.1%) and subsequently diluted on the day of the experiment
in external solution and were co-applied with GABA without pre-
incubation. Concentration-response curves of the three BDZ were
ﬁtted to the Hill equation: E(C) ¼ (Emax$[C]nH)/([C]nH þ [EC50]nH).
2.5. Quantitative RT-PCR
Twelve lumbar spinal cords and hippocampi were rapidly
removed from euthanized adult wild-type C57BL/6 and 129X1/SvJ
mice. mRNA was transcribed into cDNA using the QuantiTect
Reverse Transcription Kit (Qiagen no. 205311). Expression of
GABAAR subunits was assessed using b-actin as reference gene.
2.6. Animal experiments
All behavioral experiments were performed in 7e10 week old
female and male mice by an experimenter blinded to the genotype
or treatment of the mice. Care was taken to ensure equal numbers
of female and male mice in all groups. Permission for animal ex-
periments was obtained from the Veterin€aramt des Kantons Zürich
(license numbers 135/2009 and 126/2012). For behavioral experi-
ments, DZP, CBZ and NDMC were suspended in 0.9% saline, 1%
Tween80 and applied orally (p.o.) in all experiments.
Neuropathic painwas evoked by applying a chronic constriction
injury (CCI; Bennett and Xie, 1988) to the left sciatic nerve proximal
to the trifurcation with three loose (5-0 silk) ligatures. Mice which
showed signs of paralysis were excluded from subsequent experi-
ments. Effects of DZP and NDMC on thermal and mechanical
hyperalgesia were assessed between 7 and 14 days after surgery.
Heat hyperalgesia was quantiﬁed as the change in the latency of
Fig. 1. Potentiating effects of DZP, CBZ and NDMC on the four BDZ-sensitive GABAAR subtypes. (A) Chemical structure of DZP, CBZ, and NDMC. (BeD) GABA-evoked membrane
currents were measured in HEK293 cells transiently transfected with recombinant a1b2g2, a2b3g2, a3b3g2, and a5b2g2 GABAARs. Top panels, traces show current responses
evoked by GABA before and during application of a saturating concentration of DZP, CBZ, or NDMC (1 mM in case of DZP, and 20 mM in case of CBZ and NDMC). Light and dark traces
were recorded before and during application of the BDZ, respectively. GABA was applied at EC10 in all experiments (1 mM, 5 mM, 8 mM, and 1 mM, for a1b2g2, a2b3g2, a3b3g2, and
a5b2g2 GABAARs, respectively) for 6e10 s. Scale bars, 2 s and 200 pA. Bottom panels, concentration response curves of DZP, CBZ and NDMC obtained for the four GABAAR subtypes
at EC10 of GABA. Data are mean ± SEM. Curves represent ﬁts to the Hill equation with a baseline ﬁxed to 0. n, numbers of cells, 5e7 for all data points.
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paw withdrawal evoked by exposure of the plantar side of one
hindpaw to a deﬁned radiant heat stimulus (Hargreaves test).
Mechanical hyperalgesia was assessed with an electronic von Frey
apparatus using ﬁlament #7 (IITC, Woodland Hills, CA). Three to
four measurements were made for each time point and animal for
both heat and mechanical hyperalgesia. Percent maximal possible
effects (%MPE) were calculated as follows:
%MPE(t) ¼ 100 * (E(t)  Epredrug))/(EpreCCI  Epredrug); E(t), paw
withdrawal thresholds or latency at time point t. Epredrug, E after CCI
surgery but before DZP application; EpreCCI, E baseline before CCI
surgery.
Locomotor activity was measured in an open ﬁeld arena (20 cm
diameter) equipped with four pairs of light beams and photo-
sensors. Drugs were administered immediately before placing the
animal into the recording chamber. Locomotor activity was
analyzed for the time interval between 72 and 120 min after drug
administration.
2.7. NDMC pharmacokinetics
NDMC blood concentrations were evaluated after at various
time points after oral administration of 3, 10 and 30 mg kg1, using
the dried blood spot sampling method (Deglon et al., 2011). This
technique allows collecting multiple bleeds from the same animal
over a large time window. Four ml of whole blood were collected
and spotted onto a ﬁlter paper card from Whatman (Dassel, Ger-
many) at different time points between 0 and 48 h after NDMC
administration. NDMC blood and brain tissue concentrationwere in
addition determined at 2 h after a single oral dose of 1, 3, 10, 30, and
100 mg kg1. NDMC concentration measurements were performed
using a fully validated LC-MS-MS method (Besson et al., 2013).
Pharmacokinetic parameters were estimated using a non-
compartmental method using WinNonlin® version 5.2 (Pharsight,
Mountainview, CA, USA).
3. Results
3.1. GABAAR subtype selectivity
We ﬁrst analyzed the effect of DZP, CBZ and NDMC as positive
allosteric modulators of recombinant GABAARs expressed in
HEK293 cells (Fig. 1 and Table 1, for chemical structures see Fig. 1A).
In electrophysiological experiments, all three compounds potenti-
ated currents through a1b2g2, a2b3g2, a3b3g2 and a5b2g2
GABAARs (short a1-, a2-, a3- and a5GABAARs) but did not directly
activate GABAAR currents at the concentrations tested (up to 3 mM
for DZP, and 20 mM for CBZ and NDMC). Differences were observed
with respect to the potency and efﬁcacy of the three compounds at
the four GABAAR subtypes. DZP potentiated currents through all
four subtypes with EC50 values between 0.029 and 0.071 mM. CBZ
and NDMC were less potent with EC50 values between 0.39 and
1.1 mM and between 0.49 and 0.81 mM, respectively (Table 1). Pro-
nounced differences were found when comparing the efﬁcacy of
potentiation by the three compounds at the different GABAAR
subtypes. Potentiation by DZPwas strongest for a3GABAARs (237%),
while potentiation of the other three GABAAR subtypes ranged
between 100% and 141%. At concentrations < EC50, which are
probably more relevant to therapeutic effects of DZP, a1GABAARs
were potentiated more strongly than a2-, a3- and a5GABAARs
(Fig.1B). CBZ and DZP had very similar efﬁcacies at the four GABAAR
subtypes, but CBZ differentiated less between subtypes at sub-
saturating concentrations (Fig. 1C). NDMC potentiated a2 and
a3GABAARs to a considerably higher degree (253 and 245%) than a1
and a5 (143 and 148%) (Fig. 1D). Taken together, DZP preferred
a1GABAARs at low concentrations and a3GABAARs at high T
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concentrations. CBZ was rather non-speciﬁc at low concentrations
and preferred a3GABAARs at high concentrations. NDMC showed
the strongest potentiation at a2GABAARs over the concentration
range tested. We also determined relative afﬁnities of the three
compounds to the a1 and a2GABAARs. DZP bound both receptors
with more than ten-fold higher afﬁnities than CBZ and NDMC, but
differences in afﬁnity between the GABAAR subtypes were gener-
ally low (Table 1).
3.2. Antihyperalgesic actions
The previous study by Besson et al. (2013) has demonstrated
antihyperalgesic effects of systemically applied CBZ in mice. Phar-
macokinetic/pharmacodynamic modeling has suggested that most
of the antihyperalgesia observed in mice following CBZ adminis-
tration originated from the CBZ metabolite NDMC. We therefore
assessed antihyperalgesic actions of NDMC using the chronic
constriction injury (CCI) model of neuropathic pain. Following CCI
surgery, all mice developed pronounced mechanical and heat
hyperalgesia. Seven to 14 days after surgery, mice were treated
systemically (p.o.) with three different doses of NDMC (3, 10, or
30 mg kg1) or with vehicle. NDMC dose-dependently reduced
both heat and mechanical hyperalgesia. No signiﬁcant differences
were observed between results obtained in mice of the 129X1/SvJ
background, the genetic background of the GABAAR point-mutated
mice used in this study (Fig. 2A,B), and in C57BL/6J mice the mouse
strain most frequently used in the preclinical pain studies
(Fig. 2C,D). To ensure that NDMC induced antihyperalgesia through
the high-afﬁnity BDZ binding site located at the interface between
an a subunit and the g subunit, we made use of quadruple point-
mutated mice that carry the H / R mutation in the a1, a2, a3,
and a5 subunits, i.e. in all a subunits that can form high afﬁnity BDZ
binding sites. In these quadruple point-mutated mice, NDMC
(30 mg kg1) had completely lost its antihyperalgesic effects
(Fig. 2E,F).
3.3. Sedation
The more favorable a2/a1 selectivity proﬁle of NDMC found in
our in vitro experiments should manifest in a reduced propensity to
sedation at doses with equipotent antihyperalgesic activity. We
therefore compared the effects of DZP and NDMC (3, 10, and
Fig. 2. Antihyperalgesic actions of NDMC. Reversal of mechanical hyperalgesia (A,C,E; assessed with von Frey ﬁlaments) and thermal hyperalgesia (B,D,F; assessed in the Hargreaves
test) by NDMC 7e14 days after CCI surgery in wild-type C57BL/6J (A,B), wild-type 129X1/SvJ (C,D) and quadruple (H/ R) 129X1/SvJ point-mutated mice (E,F). Left panels, paw
withdrawal threshold or latencies (mean ± SEM) versus time after drug application. Horizontal lines indicates time interval used for the statistical analyses. Right panels, statistical
analysis. Black circles, individual mice; blue lines mean ± SEM. (AeD): ***P < 0.001, **P < 0.01, *P < 0.05 signiﬁcant versus vehicle-treated mice (ANOVA followed by Dunnett’s post
hoc test); (A) F(3,41) ¼ 19.8, n ¼ 10, 12, 11, 11 for vehicle and 3, 10 and 30 mg kg1 NDMC, respectively; (B) F(3,49) ¼ 15.2, n ¼ 14, 13, 13, 12 for vehicle and 3, 10 and 30 mg kg1
NDMC; (C) F(3,21) ¼ 16, n ¼ 6, 6, 7 and 6 mice, for vehicle and 3, 10 and 30 mg kg1 NDMC; (D): F(3,20) ¼ 9.8, n ¼ 6, 6, 6 and 6 mice, for vehicle and 3, 10 and 30 mg kg1 NDMC; (E)
unpaired t-test, n ¼ 9 and 8 for wild-type and quadruple point-mutated mice, respectively; (F) unpaired t-test, n ¼ 4 for both groups of mice. NDMC dose in panels E and F was 30
mg kg1.
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30 mg kg1 body weight) on locomotor activity in the open ﬁeld
test (Fig. 3). We performed these tests again both in C57BL/6J
(Fig. 3A,B) and 129X1/SvJ mice (Fig. 3C,D) andmonitored locomotor
activity for 6 h after drug application. Statistical analyses were
made for the time period between 72 and 120 min, which was the
time interval of maximal drug effect in the pain tests described
below. In C57BL/6J mice, DZP induced a dose-dependent reduction
in locomotor activity, which reached statistical signiﬁcance already
at a dose of 1 mg kg1 (Fig. 3A). In the same mouse strain, NDMC
reduced locomotor activity only slightly and only at the highest
dose tested (30 mg kg1) (Fig. 3B). Reduction in locomotor activity
was less pronounced in 129X1/SvJ mice (Fig. 3C,D). In these mice,
NDMC did not reduce locomotor activity at any of the doses tested,
while reduction in locomotor activity by DZP reached signiﬁcance
only at doses 10 mg kg1.
Although reduced sedative effects were expected from the more
favorable a2/a1 activity ratio of NDMC, the almost complete lack of
sedation was surprising, since NDMC still potentiated a1GABAARs
with an efﬁcacy similar to DZP (compare Fig.1). We therefore tested
whether NDMC evoked sedation in triple (H/ R) GABAAR point-
mutated (129X1/SvJ) mice in which only the a1GABAARs retained
a high afﬁnity BDZ binding site (Ralvenius et al., 2015). For brevity,
we refer to these mice as HRRR and to mice in which only
a2GABAARs retained their high afﬁnity BDZ binding site as RHRR
mice. As a pre-requisite of these experiments, we veriﬁed that re-
combinant GABAARs harboring point-mutated a subunits lose their
modulation by NDMC (Fig. S1). When locomotor sedating effects of
DZP and NDMCwere tested in HRRRmice, both compounds exerted
pronounced sedative effects. At antihyperalgesic doses (3e10 mg
kg1), locomotor activity was completely suppressed by DZP, while,
in case of NDMC, strong (>50%) suppression of locomotor activity
became apparent at doses of 10 and 30 mg kg1 (Fig. 4A,B).
Restricting the action of a BDZ site agonist to a1GABAARs thus
appears to render mice more susceptible to locomotor sedation.
The presence of a motor sedative effect by NDMC in HRRR mice but
not in wild-type mice may suggest that a2GABAAR-mediated
stimulation of locomotion (Ralvenius et al., 2015) occludes loco-
motor sedating actions of a1GABAARs. We therefore tested NDMC’s
and DZP’s effects on locomotor activity also in RHRR mice. Both
compounds indeed increased locomotion in RHRR mice (Fig. 4C,D).
It is therefore likely that this locomotor stimulant effect is related to
the anxiolytic action of a2GABAAR activation (L€ow et al., 2000).
In this context, it was interesting to see that wild-type mice of
the 129X1/SvJ genetic background were less susceptible to the
motor sedating actions of DZP and NDMC than C57BL/6 mice. A
previous study reported that GABAAR subunit expression levels
vary between mice of different genetic backgrounds and that
expression of gabra2, the gene encoding for the GABAARs a2 sub-
unit is unusually low in C57BL/6 mice (Mulligan et al., 2012). We
therefore compared its expression levels in spinal cords and
hippocampi in the two mouse strains using qRT-PCR. The a2 sub-
unit expression was higher in 129X1/SvJ than in C57BL/6 mice by
factors of 3.5 ± 0.03 (unpaired t-test, P < 0.001, n ¼ 12 for both
strains) and 4.1 ± 0.04 (P < 0.001, n ¼ 12 for both strains) for spinal
cord and hippocampus, respectively. We also found differences in
a5 subunit expression, which was higher in C57BL/6 than in 129X1/
SvJ mice by factors of 2.8 ± 0.6 (spinal cord, n ¼ 12 for both ge-
notypes) and 2.2 ± 0.4 (hippocampus, P < 0.01, n ¼ 9 and 12 for
C57BL/6 and 129X1/SvJ). No signiﬁcant differences were found
between the other subunits contributing to the high afﬁnity BDZ
binding sites (a1, a3, and g2) (Fig. S2).
To address whether a low afﬁnity BDZ binding site could be
involved in NDMC-induced sedation, we analyzed also the motor
sedative effects in the quadruple point-mutated RRRR mice
(Fig. 4E,F). NDMC left locomotor activity unchanged at doses up to
100 mg kg1 (Fig. 4F), which is 10-fold higher than the dose
required for half-maximal antihyperalgesia. By contrast, at high
doses (30 mg kg1) of DZP reduced locomotor activity also in
these mice (Fig. 5E). This observation is in line with our previous
study (Ralvenius et al., 2015). It is likely that this remaining seda-
tion occurs through the low afﬁnity-binding site in the trans-
membrane domain described by Walters et al. (2000).
Fig. 3. Locomotor sedation by DZP and NDMC. Effects of orally applied DZP (A,C), and NDMC (B,D) in C57BL/6J (A,B) and 129X1/SvJ mice (C,D) on locomotor activity in the open ﬁeld
test. Left panels, number of light beam crosses (mean ± SEM) versus time after drug application. Horizontal lines indicates time interval used for the statistical analyses. Right
panels, statistical analyses, performed for the interval 72e120 min. ***P < 0.001; **P < 0.01; *P < 0.05 signiﬁcant versus vehicle-treated mice (ANOVA followed by Dunnett’s post hoc
test. (A) F(4,28) ¼ 9.2, n ¼ 7, 7, 6, 6 and 7 for vehicle and DZP 1, 3, 10 and 30 mg kg1, respectively. (B) F(3,19) ¼ 3.2, n ¼ 6, 6, 5 and 6 for vehicle and NDMC 3, 10 and 30 mg kg1. (C)
F(3,24) ¼ 5.85, n ¼ 8, 6, 8, 6 for vehicle and DZP 3, 10 and 30 mg kg1. (D) P > 0.87, F(3,22) ¼ 0.31, n ¼ 7, 6, 7 and 6, for vehicle and NDMC 3, 10 and 30 mg kg1.
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Fig. 4. Opposing effects of a1 and a2GABAAR activation on locomotor activity. Effects of oral DZP (A,C,E), and NDMC (B,D,F) on locomotor activity in the open ﬁeld test in mice
carrying the H/ R point mutation in multiple GABAAR subtypes (a2, a3, and a5, in (A,B) or a1, a3, and a5 in (C,D)) leaving only a1GABAARs (A,B) or a2GABAARs (B,D) BDZ-sensitive.
(E,F) Same experiments as (A,B) but performed in quadruple point-mutated mice, in which all four subtypes (a1, a2, a3, and a5) of DZP sensitive GABAARs have been rendered
insensitive. Left panels, number of light beam crosses (mean ± SEM) versus time after drug application. Horizontal lines indicates time interval used for the statistical analyses. Right
panels, statistical analyses, performed for the interval 72e120 min. ***P < 0.001; **P < 0.01; *P < 0.05 signiﬁcant versus vehicle-treated mice (ANOVA followed by Dunnett’s post hoc
test. (A) F(5,29) ¼ 35.7, n ¼ 6, 6, 8, 5, 5 and 5 for vehicle and 0.3, 1, 3, 10 and 30 mg kg1, respectively); (B) F(4,25) ¼ 13.2, n ¼ 10, 5, 5, 5 and 5 for vehicle and 1, 3, 10 and 30 mg kg1.
(C) (5,25) ¼ 13.2, n ¼ 5, 6, 2, 6, 6 and 6 for vehicle and 0.3, 1, 3, 10 and 30 mg kg1. (D) F(4,22) ¼ 4.6 (n ¼ 6, 6, 5, 5 and 5 for vehicle and 3, 10, 30 and 100 mg kg1. (E) F(3,16) ¼ 4.9,
n ¼ 5, 5, 5 and 5 for vehicle and 10, 30 and 100 mg kg1. (F) F(3,23) ¼ 1.3, n ¼ 7, 6, 6 and 8 for vehicle and 30, 100 and 300 mg kg1.
Fig. 5. Pharmacokinetics of NDMC in mice. (A) Whole blood NDMC concentrations measured over time after p.o. administration of 3, 10 or 30 mg kg1 NDMC (green, blue, red lines)
to three (C57BL/6) mice per dose. Lines are ﬁts to the Bateman function. (B) Whole blood (black) and brain tissue (red) concentrations determined at 2 h after p.o. administration of
NDMC (0.3, 3, 10, 30, and 100 mg kg1). Data points represent measurements taken from individual (129X1/SvJ) mice. Brain tissue concentrations in ng mg1 were converted into
micromolar concentrations assuming a speciﬁc mass of brain tissue of 1 g ml1.
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3.4. Pharmacokinetics of NDMC
In order to relate the results of our behavioral in vivo experi-
ments to the NDMC activity proﬁles measured in vitro, we deter-
mined pharmacokinetic parameters of NDMC in C57BL/6 mice after
systemic (p.o.) administration (Fig. 5A and Table 2). Whole blood
NDMC concentrations were measured with LC-MS-MS following
single oral doses of 3, 10 and 30 mg kg1 in three mice per group.
Maximal blood levels were reached within 2e3 h. Average
maximum blood concentrations were 4.1, 6.6, and 11.5 mMand half-
life was between 4.6 and 5.6 h (Fig. 5A). We also compared whole
blood and brain tissue concentrations reached 2 h after p.o.
administration of 1e100 mg kg1 NDMC in 129X1/SvJ mice
(Fig. 5B). Average maximum whole blood concentrations ranged
from 1.0 mM (after 1 mg kg1) to 20.6 mM (after 100 mg kg1). Brain
concentrations determined at the same time point were between
3.4 and 4.0 times higher than whole blood concentrations.
3.5. Therapeutic windows of DZP and NDMC
We have previously suggested that one of the major reasons
limiting the analgesic efﬁcacy of DZP and other non-selective BDZ
in clinical practice is dose-limiting sedation, i.e. sedation already
occurs at doses much lower than those necessary for anti-
hyperalgesia (Ralvenius et al., 2015). Classical BDZs hence lack a
therapeutic window for antihyperalgesia. The present study sug-
gests that NDMC has a better a2/a1 selectivity proﬁle than DZP, and
might thus have a more favorable therapeutic window. We there-
fore compared the dose dependencies of DZP- and NDMC-induced
sedation and antihyperalgesia, assessed as reduced responses to
von-Frey ﬁlament stimulation (Fig. 6). To avoid confounding effects
of anxiolysis in sedation experiments and of sedation on anti-
hyperalgesia, we assessed sedation in triple (H/ R) point-mutated
mice, in which all GABAARs except a1 had been rendered BDZ-
insensitive. Conversely, antihyperalgesia was studied in GABAAR
a1(H/ R) point-mutatedmice to rule out confounding sedation. In
case of DZP, dose response curves showed the expected difference
in ED50 values with sedation occurring at 6-7-fold lower doses
(0.59 ± 0.08 mg kg1) than antihyperalgesia (3.4 ± 1.3 mg kg1). By
contrast, NDMC exerted antihyperalgesia and sedation with similar
ED50 values (3.4 ± 0.8 mg kg1 and 3.1 ± 0.9 mg kg1 for sedation
and antihyperalgesia, respectively).
4. Discussion
The present study suggests that NDMC might be a suitable
compound for human proof-of-concept trials assessing a potential
antihyperalgesic efﬁcacy of BDZ site agonists with improved sub-
type selectivity in chronic neuropathic pain patients. This conclu-
sion is based on three observations. (1) In recombinant receptors,
NDMC had a more favorable a2- over a1GABAARs activity ratio than
its parent compound CBZ and than the classical BDZ agonist DZP.
(2) Unlike DZP, NDMC caused either no or only modest sedation at
antihyperalgesic doses in two strains of wild-type mice. (3) Even
under conditions, which unmasked sedative effects of NDMC (i.e. in
the triple point-mutated mice), the therapeutic window of NDMC
was signiﬁcantly better than that of DZP.
In vitro, saturating concentrations of DZP and CBZ potentiated
both GABAAR subtypes with similar efﬁcacy, while NDMC clearly
favored a2- over a1GABAARs. At low concentrations (<EC50), NDMC
preferred a2GABAARs across the entire concentration range tested,
while CBZ had about similar effects on a2- and a1GABAARs and DZP
favored a1GABAARs. This result is largely consistent with a previous
report on the efﬁcacy of CBZ and NDMC at GABAAR subtypes
expressed in Xenopus laevis oocytes (Hammer et al., 2015). That
study also found an improved a2/a1 selectivity ratio for NDMC of
1.33 ± 0.06 (versus 1.02 ± 0.05 for CBZ) in human GABAARs. The
more favorable a2/a1 selectivity ratio very likely underlies the
better therapeutic window of NDMC compared to DZP. Our phar-
macokinetic analyses revealed that average peak whole blood
concentrations after analgesic doses ranged between 4.2 mM (after
3 mg kg1) and 11.5 mM (after 30 mg kg1). These concentrations
are remarkably similar to blood levels reported for human patients
during chronic treatment with antiepileptic doses of NDMC
(1000e3000 ngml1, equivalent to 3.5e10.5 mM;Haigh et al., 1987).
Assuming a cerebrospinal ﬂuid (CSF)/serum concentration ratio of
Table 2
Pharmacokinetics of NDMC in mice after p.o. administration.
Dose (mg/kg) Half-life (h) Cmax (mg/ml) AUC (h*mg/ml) Tmax (h)
3 5.6 ± 0.6 1.19 ± 2.53 11.15 ± 1.66 2.0 ± 0.9
10 4.6 ± 1.6 1.91 ± 1.34 14.72 ± 4.38 3.0 ± 0.0
30 4.7 ± 0.3 3.31 ± 1.01 32.28 ± 5.09 2.7 ± 0.6
Data are means ± SD, n ¼ 3 per group.
Fig. 6. Therapeutic windows of DZP and NDMC. a1GABAAR-mediated sedation and a2GABAAR-mediated antihyperalgesia by DZP (A) and NDMC (B,C). (A) Sedation in a2/a3/
a5(H/ R) triple point mutated mice: n ¼ 6, 6, 8, 5 and 5 for vehicle and DZP 0.3, 1, 3, 10 and 30 mg kg1, respectively; antihyperalgesia in a1(H/ R) single point-mutated mice:
n ¼ 20, 7, 14, 13 and 6, for vehicle and DZP 1, 3, 10 and 30 mg kg1, respectively. (B) Sedation in a2/a3/a5 (H/ R) triple point-mutated mice: n ¼ 10, 5, 5, 5, 5 and 4 for vehicle and
NDMC 1, 3, 10, 30 and 100 mg kg1, respectively. Antihyperalgesia in a1(H/ R) single point-mutated mice: n ¼ 6, 6, 6, 5 and 5 mice, for vehicle and NDMC 1, 3, 10 and 30 mg kg1,
respectively. Data points are mean ± SEM. (C) Same as (B) but antihyperalgesia and sedation plotted versus whole blood concentrations and estimated CSF concentrations (for
details of conversion see Discussion).
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about 0.1 (Laux and Koeppen, 1984) and a serum/whole blood ratio
of 1.7 (similar to that of DZP, Jones and Larsson, 2004), the blood
levels measured in this study correspond to roughly 0.7e2 mM
NDMC in the CSF. Thus, the drug concentrations relevant for the
in vivo analgesic effects of NDMC are above the in vitro EC50 values
at GABAARs. Accordingly, differences in the in vitro efﬁcacy at
concentrations above rather than below EC50 appear to determine
the in vivo pharmacological proﬁle of NDMC.
While no or only very weak sedation was observed in wild-type
mice after NDMC administration, locomotor sedation became
apparent when the action of NDMC was restricted to a1GABAARs,
i.e. in a2/a3/a5 (HRRR) triple point-mutated mice. This result was
not unexpected because all three compounds tested exhibited
similar efﬁcacy at a1GABAARs. Nevertheless, even when analyzed
under these conditions, the therapeutic window of NDMC was
greatly improved compared to that of DZP.
In the present study, we did not include CBZ in the in vivo ex-
periments, because, in mice, CBZ is very rapidly metabolized into
NDMC. Already 15 min after administration of CBZ, blood levels of
NDMC exceed those of CBZ (Besson et al., 2013) suggesting that
NDMC would make a major contribution to any in vivo effect seen
after CBZ administration. In humans, this conversion occurs much
more slowly with blood concentrations of CBZ exceeding those of
NDMC for more than 24 h after a single oral dose of 20 or 30mg CBZ
(Besson et al., 2015; Pullar et al., 1987). It is hence likely that, in
humans, treatment with NDMC e instead of with the parent
compound CBZewould improve the therapeutic margin and result
in less sedation at concentrations where antihyperalgesia is ex-
pected. On the other hand, after prolonged treatment of humans
steady-state NDMC concentrations exceed those of CBZ by a factor
of 2.6e3.8 (Tolbert and Bekersky, 2013). This may contribute to the
relatively (compared to DZP) low propensity of CBZ to cause
sedation during chronic treatment (Miura et al., 2002; Steru et al.,
1986). In this context, it might be worth noting that the improved
a2/a1 selectivity ratio may not only contribute to a reduced pro-
pensity to sedation but may also be relevant for other possible in-
dications such as autism spectrum disorders where activity at non-
a1GABAARs improves social interactions (Han et al., 2014; Newman
et al., 2015).
Drug discovery and development programs have yielded BDZ
site agonists with negligible activity at a1GABAARs such as L-
838,417 (McKernan et al., 2000), TPA023 (Atack et al., 2006), and
TPA023B (Atack et al., 2011). While the lack of efﬁcacy at
a1GABAARs avoids unwanted sedative and other undesired effects,
a possible limitation of these compounds is their only partial
agonistic activity at a2GABAARs. L-838,417 potentiates recombinant
a2b3g2 GABAARs only by about 40% (McKernan et al., 2000), and
potentiation of recombinant a2b3g2 GABAARs by TPA023 and
TPA023B reached only 11% and 38% of that of chlordiazepoxide
(Atack et al., 2006, 2011). By contrast, NDMC exhibited even
stronger efﬁcacy at a2GABAARs than the full agonist DZP. A corre-
lation of a2GABAAR occupancy and antihyperalgesic effects per-
formed for DZP indicates that signiﬁcant analgesia (>50%
maximum possible effect) is only achieved at about 70% receptor
occupancy even when a full agonist is used (Ralvenius et al., 2015).
This may indicate limited antihyperalgesic efﬁcacy of subtype se-
lective agonists with only partial agonistic activity at a2GABAARs.
Compared to these compounds, NDMC has a less favorable selec-
tivity ratio but much higher activity at a2GABAARs. It remains to be
seen whether the a1GABAAR activity of NDMC at antihyperalgesic
doses is still a critical limitation.
In summary, our study demonstrates that NDMC possesses not
only an improved a2/a1 GABAARs activity ratio in vitro, but also a
more favorable in vivo pharmacological proﬁle than classical BDZ.
While DZP induced half-maximal sedation at doses much lower
than those required for antihyperalgesia, NDMC elicited both ac-
tions with similar dose-dependencies. Since NDMC is a naturally
occurring metabolite of CBZ (Grigoleit et al., 1983), its safety proﬁle
is already known from its parent drug CBZ and it is very unlikely
that unexpected adverse effects emerge. NDMC might thus
constitute a useful and safe compound for investigator initiated
proof-of-concept trials in human volunteers or pain patients.
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